Shares of French drugmaker Valneva slumped more than 20% on Monday after the U.S. Food and Drug Administration suspended the ...

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

On August 25, 2025, Valneva announced that the FDA suspended the license for its chikungunya vaccine, IXCHIQ®, in the U.S. due to four new reports of serious adverse events. This suspension requires ...

Less than three weeks after lifting a pause on the use of Valneva’s chikungunya vaccine Ixchiq, the FDA has done an ...

Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S.

Valneva shares dropped after it said it will no longer be able to sell its chikungunya vaccine in the U.S. after reports linked the vaccine to adverse effects. Shares trading in New York were nearly ...

The United States Food and Drug Administration (FDA) has suspended Valneva SE’s license for IXCHIQ, citing four new reports ...

U.S. suspends Ixchiq vaccine license due to serious side effects, raising concerns over chikungunya virus spread globally.

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

The FDA suspended Valneva’s U.S. license for its chikungunya vaccine Ixchiq due to serious safety concerns, multiple ...

Mainland France has seen an explosion of chikungunya outbreaks this summer and local officials are hunting down the tiger mosquitoes responsible for spreading the virus. Meanwhile, the United States ...